MA31472B1 - Polypeptide ace2 - Google Patents

Polypeptide ace2

Info

Publication number
MA31472B1
MA31472B1 MA32464A MA32464A MA31472B1 MA 31472 B1 MA31472 B1 MA 31472B1 MA 32464 A MA32464 A MA 32464A MA 32464 A MA32464 A MA 32464A MA 31472 B1 MA31472 B1 MA 31472B1
Authority
MA
Morocco
Prior art keywords
ace2
polypeptide
dimer
present
life
Prior art date
Application number
MA32464A
Other languages
Arabic (ar)
English (en)
Inventor
Manfred Schuster
Hans Loibner
Evelyne Janzek-Hawlat
Bernhard Peball
Stefan Stranner
Robert Weik
Bettina Wagner
Original Assignee
Apeiron Biologics Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP08450052A external-priority patent/EP2108695A1/fr
Application filed by Apeiron Biologics Ag filed Critical Apeiron Biologics Ag
Publication of MA31472B1 publication Critical patent/MA31472B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/17—Metallocarboxypeptidases (3.4.17)
    • C12Y304/17023—Angiotensin-converting enzyme 2 (3.4.17.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne un polypeptide ace2 recombinant présent sous forme dimère. Ce dimère est constitué spécialement de monomères glycosylés et il est utilisé pour fabriquer des produits pharmaceutiques ayant une demi-vie prolongée.
MA32464A 2007-06-12 2009-12-30 Polypeptide ace2 MA31472B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT0091307A AT505262A1 (de) 2007-06-12 2007-06-12 Rekombinantes ace2 polypeptid
EP08450052A EP2108695A1 (fr) 2008-04-08 2008-04-08 Polypeptide Ace2
PCT/AT2008/000211 WO2008151347A1 (fr) 2007-06-12 2008-06-12 Polypeptide ace2

Publications (1)

Publication Number Publication Date
MA31472B1 true MA31472B1 (fr) 2010-06-01

Family

ID=39720296

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32464A MA31472B1 (fr) 2007-06-12 2009-12-30 Polypeptide ace2

Country Status (35)

Country Link
US (3) US8586319B2 (fr)
EP (3) EP2155871B1 (fr)
JP (1) JP5731193B2 (fr)
KR (2) KR101682240B1 (fr)
CN (2) CN101796183A (fr)
AT (1) AT505262A1 (fr)
AU (1) AU2008261591B2 (fr)
BR (1) BRPI0813942B8 (fr)
CA (1) CA2692854C (fr)
CO (1) CO6270265A2 (fr)
CR (1) CR11213A (fr)
CY (2) CY1116873T1 (fr)
DK (2) DK2155871T3 (fr)
DO (1) DOP2009000282A (fr)
EA (1) EA027399B1 (fr)
EG (1) EG27095A (fr)
ES (2) ES2670938T3 (fr)
HK (1) HK1255493A1 (fr)
HR (2) HRP20151120T1 (fr)
HU (2) HUE037877T2 (fr)
IL (1) IL202653B (fr)
LT (1) LT2543724T (fr)
MA (1) MA31472B1 (fr)
MX (1) MX2009013472A (fr)
MY (1) MY180672A (fr)
NO (1) NO2543724T3 (fr)
NZ (1) NZ581704A (fr)
PL (2) PL2543724T3 (fr)
PT (2) PT2543724T (fr)
RS (2) RS54340B1 (fr)
SI (2) SI2155871T1 (fr)
TR (1) TR201808117T4 (fr)
UA (1) UA106869C2 (fr)
WO (1) WO2008151347A1 (fr)
ZA (1) ZA200908751B (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
AT505262A1 (de) * 2007-06-12 2008-12-15 Apeiron Biolog Forschungs Und Rekombinantes ace2 polypeptid
EP2077119A1 (fr) * 2007-12-21 2009-07-08 Apeiron Biologics Forschungs- und Entwicklungsgesellschaft M.B.H. Traitement de fibroses et de maladies du foie
AT506632A1 (de) * 2008-04-09 2009-10-15 Apeiron Biolog Forschungs Und Behandlung von tumorerkrankungen
US12203113B2 (en) 2009-07-09 2025-01-21 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
HK1207564A1 (en) 2012-04-19 2016-02-05 Opko Biologics Ltd Long-acting oxyntomodulin variants and methods of producing same
KR20150037959A (ko) 2012-08-02 2015-04-08 에프. 호프만-라 로슈 아게 단량체 및 다량체 분자의 제조 방법 및 이의 용도
HUE055348T2 (hu) 2012-11-20 2021-11-29 Opko Biologics Ltd Eljárás polipeptidek hidrodinamikus térfogatának növelésére gonadotropin karboxil-terminális peptidekhez való kapcsolással
AU2014204769B2 (en) * 2013-01-14 2016-08-11 Apeiron Biologics Ag Modified ACE2 polypeptides
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
EP3230309B1 (fr) 2014-12-10 2023-03-29 OPKO Biologics Ltd. Procédés de production de polypeptides d'hormone de croissance modifiés par ctp à action prolongée
PL3310347T3 (pl) 2015-06-19 2021-12-27 Opko Biologics Ltd. Długo działające czynniki krzepnięcia i sposoby wytwarzania
MY206271A (en) 2016-07-11 2024-12-06 Opko Biologics Ltd Long-acting coagulation factor vii and methods of producing same
KR20220136369A (ko) * 2020-01-23 2022-10-07 에이바이러스 인코포레이티드 바이러스 감염의 치료 및 예방을 위한 방법 및 조성물
US11518788B2 (en) * 2020-07-10 2022-12-06 Avirus, Inc. Methods and compositions for treating and preventing viral infection
WO2021190980A1 (fr) 2020-03-22 2021-09-30 Quadrucept Bio Limited Multimères pour l'évolution d'une souche virale
EP3884957A1 (fr) 2020-03-26 2021-09-29 The University of British Columbia Procédés de traitement de virus et procédés de criblage de réactif anti-virus à l'aide d'organoïdes
WO2021205184A1 (fr) * 2020-04-09 2021-10-14 Autolus Limited Polypeptide
EP4138998A4 (fr) * 2020-04-24 2024-05-22 The Administrators of The Tulane Educational Fund Compositions et procédés visant à prévenir ou réduire les effets d'infections par des coronavirus qui se lient au domaine extracellulaire du récepteur ace2
CN113667016A (zh) * 2020-05-15 2021-11-19 普米斯生物技术(珠海)有限公司 一种构建冠状病毒抗体的平台
WO2021247675A1 (fr) 2020-06-02 2021-12-09 Ngm Biopharmaceuticals, Inc. Agents liant les coronavirus et leurs utilisations
DE102020207224A1 (de) 2020-06-09 2021-12-09 Christoph Karle Protein oder Peptid, insbesondere zur Prophylaxe und/oder Behandlung einer durch Coronaviren, insbesondere SARS-CoV-2-Viren, hervorgerufenen Infektion oder Infektionskrankheit und/oder einer Folgekrankheit davon
CA3179834A1 (fr) * 2020-06-25 2021-12-30 David S. Block Proteines de fusion ace2-fc et methodes d'utilisation
WO2022008642A1 (fr) 2020-07-08 2022-01-13 Apeiron Biologics Ag Traitement d'une infection par le sras-cov-2 avec une combinaison de cibles
TW202216777A (zh) * 2020-07-10 2022-05-01 美商生質分子控股有限責任公司 四面體抗體
US20230303654A1 (en) * 2020-08-11 2023-09-28 City Of Hope Compositions and uses of sars-cov-2 targeted chimeric antigen receptor modified nk cells
WO2022037699A1 (fr) * 2020-08-21 2022-02-24 Westlake University Oligomères d'ace2 modifiés et leurs utilisations
KR102725210B1 (ko) * 2020-10-05 2024-11-04 한양대학교 산학협력단 안정화된 Ace2 변이체, 이를 이용한 Ace2-Fc 융합단백질 및 COVID-19 예방 또는 치료용 약학 조성물
CN112280764A (zh) * 2020-11-18 2021-01-29 通用生物系统（安徽）有限公司 一种新冠重组ace2蛋白在哺乳动物细胞中的生产方法
EP4011387A1 (fr) 2020-12-11 2022-06-15 IMBA-Institut für Molekulare Biotechnologie GmbH Neutralisation supérieure du sars-cov-2 par la conversion de l'enzyme 2 de l'angiotensine humaine déglycosylée
US20220226489A1 (en) 2021-01-20 2022-07-21 Singh Biotechnology, Llc Therapeutics directed against coronavirus
WO2022184659A1 (fr) 2021-03-01 2022-09-09 Quadrucept Bio Limited Domaines d'anticorps et multimères
WO2022207918A1 (fr) 2021-04-02 2022-10-06 Apeiron Biologics Ag Thérapie anti-covid-19
WO2023023424A1 (fr) * 2021-08-19 2023-02-23 Phenom Pharmaceuticals, Inc. Compositions et méthodes pour le traitement du sars-cov-2
KR102834587B1 (ko) * 2021-09-16 2025-07-17 인에이블앱 주식회사 안지오텐신전환효소 2 수용체 및 이의 용도
CN113897346A (zh) * 2021-09-16 2022-01-07 四川大学 能够提高与SARS-CoV-2 S蛋白亲和力的ACE2突变组合及应用
DE102023118690A1 (de) 2023-07-14 2025-01-16 Christoph Karle Protein oder Peptid, insbesondere zur Prophylaxe und/oder Behandlung einer Infektion und/oder Infektionskrankheit und/oder einer Folgeerkrankung davon

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194556B1 (en) * 1997-12-11 2001-02-27 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therfor
US6610497B1 (en) * 1997-12-11 2003-08-26 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor
US6989363B1 (en) * 1997-12-11 2006-01-24 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor
PT1515752E (pt) * 2002-06-19 2009-03-05 Univ Health Network Activação de ace2 para o tratamento de doença cardíaca, pulmonar e renal e de hipertensão
US20040209344A1 (en) 2002-09-09 2004-10-21 Pantoliano Michael W. Crystal structure of angiotensin-converting enzyme-related carboxypeptidase
EP1723962A1 (fr) * 2005-05-19 2006-11-22 IMBA-Institut für Molekulare Biotechnologie GmbH Utilisation des inhibiteurs du système de rénine-angiotensine pour le traitement des lesions poumonaires.
AT504443B1 (de) * 2006-10-19 2008-11-15 Apeiron Biolog Forschungs Und Verfahren zur bestimmung der aktivität von ace2
EP2108695A1 (fr) * 2008-04-08 2009-10-14 Apeiron Biologics Forschungs- und Entwicklungsgesellschaft M.B.H. Polypeptide Ace2
AT505262A1 (de) * 2007-06-12 2008-12-15 Apeiron Biolog Forschungs Und Rekombinantes ace2 polypeptid
AT506258A1 (de) * 2007-12-18 2009-07-15 Apeiron Biolog Forschungs Und Behandlung inflammatorischer krankheiten
AT506632A1 (de) * 2008-04-09 2009-10-15 Apeiron Biolog Forschungs Und Behandlung von tumorerkrankungen

Also Published As

Publication number Publication date
EP2155871B1 (fr) 2015-08-12
JP2011519264A (ja) 2011-07-07
PL2543724T3 (pl) 2018-08-31
UA106869C2 (uk) 2014-10-27
HUE037877T2 (hu) 2018-09-28
AU2008261591A1 (en) 2008-12-18
TR201808117T4 (tr) 2018-07-23
CA2692854A1 (fr) 2008-12-18
RS54340B1 (sr) 2016-02-29
US20180289779A1 (en) 2018-10-11
WO2008151347A1 (fr) 2008-12-18
HRP20151120T1 (xx) 2015-11-20
US20100310546A1 (en) 2010-12-09
CN101796183A (zh) 2010-08-04
NZ581704A (en) 2012-05-25
CR11213A (es) 2010-04-20
US10716833B2 (en) 2020-07-21
CN104450654A (zh) 2015-03-25
EP2543724A2 (fr) 2013-01-09
EA027399B1 (ru) 2017-07-31
EA201000002A1 (ru) 2010-08-30
HUE028012T2 (en) 2016-11-28
SI2543724T1 (en) 2018-07-31
ZA200908751B (en) 2010-07-28
DOP2009000282A (es) 2010-03-31
IL202653B (en) 2018-01-31
BRPI0813942B1 (pt) 2019-08-20
US20140099297A1 (en) 2014-04-10
PT2155871E (pt) 2015-10-26
JP5731193B2 (ja) 2015-06-10
HRP20180856T1 (hr) 2018-08-24
US8586319B2 (en) 2013-11-19
SI2155871T1 (sl) 2015-11-30
CY1116873T1 (el) 2017-04-05
CA2692854C (fr) 2017-07-04
EP2155871A1 (fr) 2010-02-24
DK2155871T3 (en) 2015-11-09
ES2550390T3 (es) 2015-11-06
AT505262A1 (de) 2008-12-15
HK1136602A1 (en) 2010-07-02
EP2543724A3 (fr) 2013-02-20
CY1120426T1 (el) 2019-07-10
EG27095A (en) 2015-05-28
IL202653A0 (en) 2011-08-01
LT2543724T (lt) 2018-06-25
DK2543724T3 (en) 2018-05-28
MY180672A (en) 2020-12-05
PT2543724T (pt) 2018-06-11
PL2155871T3 (pl) 2015-12-31
EP3375872A1 (fr) 2018-09-19
AU2008261591B2 (en) 2014-08-07
EP2543724B1 (fr) 2018-03-21
HK1255493A1 (zh) 2019-08-16
BRPI0813942B8 (pt) 2021-05-25
ES2670938T3 (es) 2018-06-04
RS57292B1 (sr) 2018-08-31
BRPI0813942A2 (pt) 2014-12-30
KR20100040809A (ko) 2010-04-21
CO6270265A2 (es) 2011-04-20
KR20160054045A (ko) 2016-05-13
NO2543724T3 (fr) 2018-08-18
KR101682240B1 (ko) 2016-12-06
MX2009013472A (es) 2010-06-25

Similar Documents

Publication Publication Date Title
MA31472B1 (fr) Polypeptide ace2
BRPI0510527A (pt) método de estabilização de proteìnas
IL232501A0 (en) Stable analogs of medicinal peptides and polypeptides
CR9975A (es) Anticuerpos antagonistas dirigidos contra el péptido relacionado con el gen de calcitonina
WO2010007622A3 (fr) Interférons à longue durée d’action et dérivés de ceux-ci et procédés pour ceux-ci
EA200602137A1 (ru) Гидрогелевые препараты интерферона
DE602005019175D1 (de) Verfahren und zusammensetzungen zur messung von natriuretischen peptiden und verwendung dafür
BRPI0911984A2 (pt) sequências de aminoácidos direncionadas contra cxcr4 e outros compostos gpcrs compreendendo os mesmos
MX2010002769A (es) Preparacion recombinante de fracciones de bromelaina seleccionadas.
ATE439828T1 (de) In der mundhíhle dispergierbare feste pharmazeutische form
WO2007100874A3 (fr) Compositions comprenant des peptides avec des acides aminés non naturels et leurs procédés d'utilisation
MA34453B1 (fr) Utilisation d'une eau appauvrie en deutèrium pour traiter la résistance à l'insuline
IN2015DN01371A (fr)
FR2865011B1 (fr) Cuve notamment destinee au traitement sous pression d'objets
BG66517B1 (bg) Супресор на ендогенния човешки гама - интерферон
FR2868704B1 (fr) Utilisation de lipides pour ameliorer la biodisponibilite de principes actifs proteiques en formulations injectables sous cutanees ou intra-musculaires
WO2019050872A9 (fr) Procédés et compositions destinés à l'expression améliorée de protéines recombinantes
UA93658C2 (en) Cell surface glycoprotein
EA200971092A1 (ru) Vegf-d мутанты и их применение
UA94716C2 (ru) Кальциепептидный компонент для снижения веса тела
IL169256A (en) Polypeptide having metalloprotease activity, nucleic acid encoding it and pharmaceutical composition comprising it
WO2006041829A3 (fr) Peptides antagonistes a la fonction chimiotactique de c5a de la proteine de liaison de la vitamine d
RU2008148880A (ru) Семейство пептидов, обладающее противовирусной активностью
DE602005020755D1 (de) Peptidträger für die verabreichung von arzneimitteln
AU2003260306A1 (en) Bicyclic oligopeptides